Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)~* Diagnosis of Coronary Artery Disease (CAD)~* Stable lipid-lowering therapy for 12 weeks~* On maximally tolerated statin therapy with at least 1 statin at a dose greater than zero, per Investigator judgment~* Stable low-fat diet for 8 weeks~* Stable weight for 6 weeks~Exclusion Criteria:~* Significant health problems in recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, orthostatic hypotension, uncontrolled hypertension, blood disorders, liver disease, cancer, or digestive problems~* Receiving apheresis treatment or last apheresis treatment within 8 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mipomersen (Type: EXPERIMENTAL): Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a placebo subcutaneous injection once a week for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).